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Sul'lp_inary 
The integrin very late antigen, (VLA-4) ce~l and its counter receptor vascular cell adhesion 
molecule I (VCAM-1) are involved in B cell maturation and pre-B cell attachment to bone marrow 
stroma cells. We have analyzed whether heat-stable antigen (HSA), a marker for immature leukocytes, 
is involved in such cell adhesion phenomena. HSA is a glycolipid-anchored, highly glycosylated 
surface protein differentially expressed on cells during the maturation of both the hematopoietic 
and nervous systems. We found that pre-B cells lacking HSA (due to targeted disruption of both 
alleles) can still bind via VLA-4 to tumor necrosis factor ce-stimulated endothelioma cells. This 
binding, however, cannot be blocked by an anti-VCAM-1 antibody. Restoration of liSA expression 
restores the inhibitable VCAM-1 binding. We also found that pre-B cells lacking HSA did not 
bind to the FN40 fragment of fibronectin but reexpression  of HSA restored VLA-4-mediated 
binding to fibronectin. Thus, expression of HSA on pre-B cells modifies the binding specificity 
of VLA-4 for two known ligands. 
"~ egulated adhesion of lymphocytes is crucial both for matu- 
.L ~. ration in primary lymphoid organs as well as for effector 
functions in the periphery. Several cell surface receptors have 
been reported to be involved in this adhesion, depending on 
the cell type and the maturation stage. During the differenti- 
ation of B cells, attachment of pre-B cells to bone marrow 
stroma cells can be blocked by antibodies against the inte- 
grin very late antigen, (VLA-4) o~4B1  or its counter receptor 
vascular cell adhesion molecule 1 (VCAM-1) suggesting that 
they play a major role in the binding (1-4).  The heat-stable 
antigen (HSA; mouse CD24) is a heavily glycosylated sur- 
face protein expressed on immature neural (5) and hemato- 
poietic cells and is widely used in the mouse as a maturation 
marker for lymphocytes (6, 7). Results have been published 
suggesting the involvement of HSA in lymphocyte adhesion 
and in delivery of costimulatory signals  for T  cells (8,  9). 
Since HSA is most strongly expressed on immature B cells 
in the bone marrow, we asked whether it could also influence 
pre-B  cell adhesiveness. 
Materials  and Methods 
Reagents and Antibodies.  The mAbs used in this study were 
M1/69 directed against HSA (mCD24; reference  10), MK-2 against 
mouse VCAM-1 (CRL 1909; American Type Culture Collection 
[ATCC], RockviUe, MD; reference 1) and PS-2 against the inte- 
grin chain ce4 (2), M17/4.4.11.9 against CD11a (TIB217; ATCC; 
M. Hahne and R. H. Wenger contributed equally to this paper. 
reference 11); 9EG7 directed against the integrin chain/31 (12), 
13CA7 directed against an as yet undefined, TNF-c~-inducible  an- 
tigen on the surface of brain-derived endotheliama (bEND.3) cells 
(Hahne, M., and D. Vestweber, unpublished observations). The 
mouse E- and P-selectin antibodies have been recently described 
(13). Human recombinant TNF-ce (8.72  x  106  U/rag) was a 
generous gift of the Knoll AG (Ludwigshafen, Germany). 
Cell Culture and Transfection.  The brain endothelioma bEND.3 
(a gift from W. Risau, Max-Planck-Institute for Physiological  and 
Clinical Research, Bad Nauheim,  Germany, and L.  Williams, 
Ludwig Institute for Cancer Research, Melbourne, Australia) was 
cultured as described (13). The Abelson murine leukemia virus (A- 
MuLV)-transformed pre-B lines were cultured in vitro in IMDM 
(GIBCO BRL, Gaithersburg, MD) supplemented with 10% FCS, 
50  /~M  2-ME at  37  ~  and  7.5%  CO2. The  HSA  expression 
plasmid pHSEX62.8 was described previously  (14) and DNA prep- 
aration was done according to standard procedures (15). Pre-B cell 
lines were transfected by electroporation of 2  x  107 cells in 350 
/~1 medium without FCS using 50 #g Xmn I-linearized  pHSEX62.8 
(950/~F, 225 V) in a 0.4-cm electroporation  cuvette  (Bio-Rad  Labora- 
tories, Richmond, CA). Stable expression was achieved  by coelec- 
troporation with pHyg72 (contains the hygromycin-resistance  gene 
under the control of the HSV-tk promoter) and selection with 1 
mg/ml hygromycin B (Calbiochem Corp., La Jolla, CA). Mono- 
clonal hygromycin-resistant  HSA + cell lines were obtained by lim- 
iting dilution. 
Abelson Virus Transformation.  Bone marrow cells from isolated 
femurs were flushed with medium,  counted,  centrifuged,  and 
resuspended at 2-3  x  106 cells in 0.25 mt medium. They were 
mixed with 1 ml fresh supernatant of a transformed NIH3T3 cell 
line (54C12) that produces a replication  defective  A-MuLV  (16, 17). 
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resulting mixture was incubated at 37~  and 7.5% CO2 for 3 h. 
After dilution with medium (1:10) and addition of  3% molten low 
melt SeaPlaque agarose (FMC BioProducts, Rockland, ME) to a 
final concentration of 0.6% the cells were placed in 1-ml aliquots 
on a 1-ml 0.6% soft agarose bottom layer in 3.5-cm petri dishes 
(Falcon Labware, Oxnard, CA). The dishes were incubated for 12 
d and transformed  clones were picked and propagated in liquid sus- 
pension culture. The clones were classified  by flow cytometry as 
pre-B because they were surface positive for the B-lineage marker 
B220 (CD45) and negative for surface IgM. 
Flow Cytomet~.  Analysis  was performed  on a FACScan  |  cytom- 
eter (Becton  Dickinson & Co., Mountain View, CA) using LYSISII 
software. Cells were stained with the following mAB conjugates: 
M1/69-FITC, PS-2-biotin, 9EG7-FITC. Biotinylated mAbs were 
revealed with streptavidin  coupled to PE (Southern Biotechnology 
Associates, Birmingham, AL). Dead cells were excluded by elec- 
tronic gating on propidium iodide-negative cells. 
CellAdhesion Assays.  Endothelioma cells were plated at a den- 
sity of 2  x  104 cells/well on 96-well microtiter plates two d be- 
fore the test. TNF-c~ activation of the endothelioma cells was for 
16 h with human recombinant TNF-cr followed by two washes 
in HBSS (Biochrom, Berlin, Germany). Pre-B cells were harvested, 
washed once in 37  ~ HBSS, and added to the microtiter plate (2 
x  10  s cells in 200/zl/well)  that was rotating at 75 rpm (with 1 
cm orbit diameter). After 20 min at 37~  unbound pre-B cells 
were removed by gentle flicking. Bound cells were fixed with 1% 
glutaraldehyde in PBS for 2-3 h at 7~  followed by three more 
washes with HBSS. None of the mAbs against HSA tested 011d, 
M1/69, 79, B2A2) had any inhibitory effect  in our binding system 
(data not shown). 
Fibronectin  Adhesion  Assay.  96-well  plates were coated with FN- 
40, 1/zg/well (Telius Pharmaceuticals, San Diego, CA), or oval- 
bumin,  1/zg/well in PBS overnight at 37~  Plates were subse- 
quently blocked by incubation with 10% heat-inactivated  FCS in 
PBS (attachment buffer) at 37~  Pre-B cells (2  x  10  s cells) were 
added in 200/zl attachment buffer to each well and allowed to bind 
for 30 min at 37~  in 5% CO2. Nonadherent cells were then 
washed off  with attachment buffer and bound cells counted as de- 
scribed above. 
Results and Discussion 
Pre-B cell clones deficient for HSA were generated by trans- 
forming bone marrow-derived cells from a chimeric mouse 
generated by the injection of ES cells carrying deletions in 
both alleles of the HSA gene (Wenger, R. H., M. Kopf, L. 
Nitschke, M. C. Lamers, G. K6hler, and P. J. Nielsen, manu- 
script submitted for publication). The HSA deficiency of one 
of these clones (termed N232.18)  is shown in Fig.  1 using 
the anti-HSA mAb M1/69 in FACS  |  analysis. This clone was 
transfected with an HSA expression plasmid (14) and numerous 
clones were obtained that stably expressed HSA on the sur- 
face (three cell lines,  18H8,  18H15,  and 18H18,  are shown 
in Fig.  1). 
We tested the ability of HSA-  N232.18  pre-B cells, and 
the stable HSA + transfectants 18H8,  18H15, and 18H18 to 
bind to bEND.3. As shown in Fig. 2, both the HSA-deficient 
N232.18  cells and the HSA + transfectants strongly bound 
to bEND.3  cells activated for 16 h with TNF-ce, but not 
to unstimulated cells. 
control  18H8 




Figure 1.  Flow  cytometric  (FACS  ~  analysis  of the HSA- pre-B cell 
line N232.18 and the HSA+ transfectants  18H8, 18H15, and 18H18. Cells 
were stained  with FITC-conjugated  anti-HSA mAb M1/69 (19) and ana- 
lyzed  on a FACscan  |  cytometer.  Control  staining  were  with goat anti-rat 
Ig (H+L) coupled to FITC. 
It has been recently reported that bEND.3 cells express 
VCAM-1 at maximal levels after 16 h of TNF-c~ stimulation 
whereas intercellular adhesion molecule-1 (ICAM-1) is hardly 
induced on these cells and E- and P-selectin  are transiently 
induced and return again to basal levels, 16 h after stimula- 
tion (13). Therefore, we tested whether VCAM-1 mediated 
the binding of the four pre-B cell clones. As shown in Fig. 
3 A, mAb MK-2 against mouse VCAM-1 indeed blocked 
the binding of the three HSA transfectants. However, binding 
of the HSA deficient pre-B cell clone N232.18  could not be 
blocked with this antibody (Fig. 3 A). Binding of all four 
pre-B cell clones was also not blocked by adhesion blocking 
antibodies against mouse E- and P-selectin  (not shown) or 
by the control mAb 13CA7. 
Despite the fact that the anti-VCAM-1 mAb could not 
block adhesion of the HSA-deficient pre-B cells to activated 
bEND.3 cells, this adhesion was completely blocked by the 
anti-VLA-4 mAb PS/2 (Fig. 3 B). The same inhibitory effect 
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Figure 2.  Adhesion of the HSA-  pm-B cell line N232.18  and  the 
HSA* transfectants 18H8, 18H15, and 18H18 to brain endothelioma cells. 
Pre-B ceils were incubated with untreated and 16 h TNF-activated  bEND.3 
endothelioma cells in 96-well microtiter plates.  Each measurement was 
done in three wells and one of three simihr series of experiments is depicted 
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Figure 3.  The  effect  of antibodies on  the  adhesion  of the  HSA- 
N232.18 FeB celJs and the HSA + transfectants 18H8, 18H15, and 18H18 
to TNF-c~-activated bEND.3 cells. Cell binding in the absence of anti- 
bodies was defined as 100%. Inhibition of cell adhesion with antibodies 
was tested with fivefold concentrated hybridoma supernatants of mAb 
MK-2 (anti*VCAM-1  [1}) (A), and plain supernatant of the mAb PS-2 
(anti-o~4 [2]) (B). As a control, the endothelial ceils were incubated with 
fivefold concentrated hybridoma supernatants  of mAb 13CA7 (recognizes 
an as yet unidentified surface marker on TNF-cx-acrivated  bend.3; Hahne, 
M., and D. Vestweber, unpublished observations)  (A) or plain superna- 
tant of the mAb M17/4.4.11  (anti-LFA-1 [18]) (B). Antibody incubations 
were for 15 rain on ice before the adhesion assays. None of the anti-HSA 
mAbs tested (M1/69, J11d, B2A2,  79) inhibited binding of pre-B cells 
to bEND.3 cells. 
was seen on the binding of all three HSA transfectants.  (Fig. 
3 B). Thus, independent of the expression of HSA, all tested 
pre-B call clones bound via VLA-4 to activated endothdioma 
cells. However, these ceils apparently bind to VCAM-1 only 
when they express HSA. We conclude that the lack of HSA 
expression changes the binding characteristics of VLA-4 such 
that MK-2-inhibitable binding to VCAM-1 is abolished.  It 
is unclear, at present, which endothelial ligand is bound by 
VLA-4 in the absence of HSA. It could be either another 
domain of VCAM-1 not blocked by MK-2 or an indepen- 
dent counter receptor,  the existence of which has been re- 
cently suggested (18, 19). 
Fibronectin is a second ligand for VLA-4 and binds to a 
different  site  on VLA-4  than  VCAM-1  (20).  We  tested 
whether the HSA- deficient pre-B cell clone N233.18 differs 
from the HSA transfectants in its ability to bind to the 40-kD 
trypsin fragment of plasma fibronectin (FN-40) that contains 
the CS-1 binding site for VLA-4 (21). As shown in Fig. 4, 
only the  HSA +  transfectants  but  not  the  HSA  deficient 
pre-B  ceils bound to  FN-40.  The binding of the HSA + 
transfectants  could be inhibited by the anti-c~4 mAb PS/2 
but not by a  control antibody against lymphocyte func- 
tion-associated antigen 1 (LFA-1). 
The binding of VLA-4 to both of its two known ligands, 
VCAM-1 and fibronectin, was altered by the loss of HSA. 
The mechanism by which HSA expression  influences the 
binding specificity of VLA-4 is at present unknown. Interest- 
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Figure 4.  Adherence of the HSA- N232.18 pre-B cells and the HSA+ 
transfectants  18H15 and 18H18 to the 40-kD chymotryptic fragment of 
fibronectin (FN-40). Call binding in the absence of antibodies was defined 
as 100%. Inhibition of adhesion was tested with plain supematants of PS-2 
(anti-oe4 [2]) or M17/4.4.11 (anti-LFA-1 [11]) as a control. Bound cells 
were counted as described  above. 
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other heavily glycosylated surface protein, where it seems that 
expression of CD43 can interfere with adhesion between the 
integrin LFAol and ICAM-1 (24). It is well documented that 
the binding activity of the integrins is regulated through con- 
formational changes which are influenced either by extracel- 
lular ligands  or by modifications transmitted  from within 
the cell (see 23-25 for reviews). Conceivably, HSA could in- 
duce such conformational changes either directly by associa- 
tion with VLA-4 on the cell surface,  or indirectly by trans- 
mitting  a  signal  into  the  cell.  Adhesion  mediated by the 
integrin VLA-4 can be activated by incubation of cells with 
Mn  2+  and this activation correlates with increased binding 
of the mAb 9EG7 (12).  HSA does not seem to change the 
ability to activate VLA-4 since, for HSA- as well as HSA + 
cells, binding of mAb 9EG7 was stimulated to a comparable 
extent  by Mn  2+  (not  shown).  The  surface  expression  of 
VLA-4 was also not changed by loss of HSA expression since 
VLA-4 levels on all four pre-B cell lines described were similar 
when examined by FACS  |  using the anti-c~4 mAb PS-2 and 
the anti-~l  mAb 9EG7  (not  shown). 
The influence of HSA on VLA-4-mediated adhesion should 
be examined in other pre-B  lines as well as in calls representing 
different stages of the B and T cell maturation since this would 
have important implications both for the development of he- 
matopoietic cells as well as their function in the periphery. 
It has been shown that both murine and human bone marrow 
stromal cells and human bone marrow-derived fibroblasts ex- 
press VCAM-1  and that  the adhesion of B cell precursors 
to  accessory cells  in  the bone marrow is mediated by the 
VCAM-1/VLA-4 ligand-receptor pair (1-4). Blocking these 
interactions prevents B cell development. The regulation of 
HSA expression during cell maturation  could be a mecha- 
nism for associating cells of various maturation  stages with 
specific developmental compartments.  Similarly,  the down- 
regulation of HSA during the maturation of peripheral B cells 
and monocytes, could change their ability to home and ex- 
travasate.  These possibilities are being investigated in homo- 
zygote HSA-knockout mice. 
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